Glenmark Pharmaceuticals LtdGlenmark Pharmaceuticals Ltd - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This page contains a Q&A table about Glenmark Pharmaceuticals Ltd. Check the bottom of the page for potential risks for Glenmark Pharmaceuticals Ltd based on industry, geography and size. The Sustainability assessment for Glenmark Pharmaceuticals Ltd indicates the company's transparency towards the United Nations SDGs.

Glenmark Pharmaceuticals Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.1; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.

SDG Transparency Score for Glenmark Pharmaceuticals Ltd 
Low
0 - 3
Medium
4 - 6

8.1

High Impact
7 - 10
Last Score Update: 2023-07-01
What drives the score for Glenmark Pharmaceuticals Ltd 
8.0

Environmental

8.0

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
18Pacific Biosciences of California Inc
8.2
High
18Valneva SE
8.2
High
36Glenmark Pharmaceuticals Ltd
8.1
High
36Adcock Ingram Holdings Ltd
8.1
High
36Alkem Laboratories Ltd
8.1
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Glenmark Pharmaceuticals Ltd have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd report the average age of the workforce?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose cybersecurity risks?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd offer flexible work?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd conduct supply chain audits?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose water use targets?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Glenmark Pharmaceuticals Ltd have a product recall in the last two years?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose incidents of discrimination?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Glenmark Pharmaceuticals Ltd issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose parental leave metrics?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Glenmark Pharmaceuticals Ltd involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose its waste policy?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd report according to TCFD requirements?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose energy use targets?

LockedSign up for free to unlock

Does Glenmark Pharmaceuticals Ltd disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Glenmark Pharmaceuticals Ltd have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Glenmark Pharmaceuticals Ltd
These potential risks are based on the size, segment and geographies of the company.

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830, an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISC 17536, an oral transient receptor potential ankyrin-1 antagonist, which has completed Phase 2a clinical trial for the treatment of diabetic peripheral neuropathy; ISB 1302, a HER2 X CD3 beat bispecific antibody, which is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; ISC XXXXX, an HPK1 inhibitor for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma t for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was founded in 1977 and is based in Mumbai, India.

Sorry!

Failed to process!